BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10898321)

  • 1. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group.
    Causse X; Payen JL; Izopet J; Babany G; Girardin MF
    J Hepatol; 2000 Jun; 32(6):1003-10. PubMed ID: 10898321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.
    Sauleda S; Juárez A; Esteban JI; Altisent C; Ruiz I; Puig L; Esteban R; Guardia J
    Hepatology; 2001 Nov; 34(5):1035-40. PubMed ID: 11679976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.
    Shiffman ML; Hofmann CM; Contos MJ; Luketic VA; Sanyal AJ; Sterling RK; Ferreira-Gonzalez A; Mills AS; Garret C
    Gastroenterology; 1999 Nov; 117(5):1164-72. PubMed ID: 10535880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Bräu N
    Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
    Pineda JA; Caruz A; Rivero A; Neukam K; Salas I; Camacho A; Palomares JC; Mira JA; Martínez A; Roldán C; de la Torre J; Macías J
    Clin Infect Dis; 2010 Oct; 51(7):788-95. PubMed ID: 20804372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
    Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group.
    Ouzan D; Babany G; Valla D; Opolon P
    J Viral Hepat; 1998 Jan; 5(1):53-9. PubMed ID: 9493517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels.
    Mandorfer M; Reiberger T; Payer BA; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Puoti M; Zangerle R; Trauner M; Peck-Radosavljevic M
    J Viral Hepat; 2014 Jan; 21(1):33-41. PubMed ID: 24329855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
    Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S
    AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin.
    Nasti G; Di Gennaro G; Tavio M; Cadorin L; Tedeschi RM; Talamini R; Carbone A; Tirelli U
    AIDS; 2001 Sep; 15(14):1783-7. PubMed ID: 11579239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection.
    Puoti M; Rossi S; Forleo MA; Zaltron S; Spinetti A; Putzolu V; Rodella A; Carosi G
    J Hepatol; 1998 Jul; 29(1):45-52. PubMed ID: 9696491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients.
    Landau A; Batisse D; Duong Van Huyen JP; Piketty C; Bloch F; Pialoux G; Belec L; Petite JP; Weiss L; Kazatchkine MD
    AIDS; 2000 May; 14(7):839-44. PubMed ID: 10839592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
    Mira JA; Gutiérrez-Valencia A; Gil Ide L; Merino D; Rivero A; Ríos-Villegas MJ; Delgado M; González-Serrano M; Collado A; Torres-Tortosa M; Omar M; López-Ruz MA; Macías J; Arponen S; Pineda JA
    Clin Infect Dis; 2009 Oct; 49(8):e84-91. PubMed ID: 19772388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.